Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 21 July 2017 | By Michael Mezher
The European Medicines Agency (EMA) on Friday said it plans to suspend the marketing authorization for three gadolinium contrast agents and restrict the use of others after a review by the agency's Pharmacovigilance Risk Assessment Committee (PRAC) confirmed evidence of gadolinium accumulation in patients' brains months after being injected.
EMA says the move is a precautionary measure, as there is currently no evidence that gadolinium accumulation in the brain poses a health risk to patients.
The US Food and Drug Administration (FDA) is also currently reviewing the safety of gadolinium contrast agents, but as of May 2017 the agency says it has not identified any adverse effects of gadolinium retention in the brain and that restricting their use "is not warranted at this time."
Specifically, EMA says it plans to suspend the authorizations of three intravenous linear gadolinium contrast agents, Magnevist (gadopentetic acid), Omniscan (gadodiamide) and Optimark (gadoversetamide).
Two other intravenous linear products—Primovist (gadoxeticacid) and Multihance (gadobenic acid)—will continue to be available, as EMA says they "can be used for imaging poorly vascularized hepatic lesions, especially in delayed phase imaging, that cannot be adequately suited with other agents."
EMA is also recommending restricting the use of the intra-articular form of Magnevist, which the agency says "can continue to be used for joint scans because the dose of gadolinium used for joint injections is very low."
Additionally, EMA says that macrocyclic gadolinium contrast agents "can continue to be used in their current indications but in the lowest doses that enhance images sufficiently and only when unenhanced body scans are not suitable."
With the conclusion of EMA's review, the recommendations will now be forwarded to the European Commission, which will issue a legally binding decision on the agency's recommendations.
Tags: Gadolinium
Regulatory Focus newsletters
All the biggest regulatory news and happenings.